Russia's Sputnik Light vaccine shows 70% effectiveness against the Delta variant of COVID-19 three months after injection and the one-shot product is likely to become the country's main vaccine, Russia's sovereign wealth fund said on Wednesday.<br /><br />The findings are part of a Russian push to promote Sputnik Light as an effective standalone vaccine and as a booster that can be combined with non-Russian vaccines.<br /><br />RDIF, the wealth fund which markets Sputnik Light abroad, cited data submitted by the developer, the Gamaleya Institute, to medical website medRxiv ahead of a peer review. The data was based on 28,000 participants who received a dose of Sputnik Light, and an unvaccinated control group of 5.6 million.<br /><br />Russia is battling soaring infections and hesitancy about vaccines at home, while struggling to compete in some markets with Western vaccines developed by Pfizer, Moderna and AstraZeneca.<br /><br />Source: Reuters
